Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single-arm, Phase II Study to Evaluate the Efficacy and the Feasibility of Bevacizumab (Avastin) Based on a FOLFOXIRI Regimen Until Progression in Patients With Previously Untreated Metastatic Colorectal Carcinoma(OPAL-Study)

NCT00940303 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00940303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00940303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single-arm, Phase II Study to Evaluate the Efficacy and the Feasibility of Bevacizumab (Avastin) Based on a FOLFOXIRI Regimen Until Progression in Patients With Previously Untreated Metastatic Colorectal Carcinoma(OPAL-Study)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
February 28, 2014
Enrollment
97 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer